Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The study is trying to answer the following question: "Can we use non-invasive imaging to
evaluate the response of atopic dermatitis (eczema) to Dupixent (dupilumab)?"